+34 679 490 537info@nanbiosis.com

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit has implemented the ISO9001 certification forstandard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
BIO2013-41019-P ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS MINECO Participant
2014SGR-132 Basic and Applied Microbiology AGAUR Participant
BIO2016-76063-R DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES MINECO Working package
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications


2016

  • Corchero J.L.. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

25 Jun

How engineered protein helps Nanomedicine againts Cancer

The use of protein nanoparticles as biomaterials have been rising in recent years due to their characteristics: high biocompatibility, structural versatility, biodegradability and plasticity of design. We can later incorporate peptide ligands for specific targeting as fusion proteins and use these nanoparticles for targeted nanomedicine. However, not all proteins can be used as scaffolds for targeted drug delivery, as they need to meet certain criteria. First, it is crucial that the proteins used as a scaffold allow site-specific drug conjugation. The stability and proteolysis resistance of these proteins is also important to remain assembled during the bloodstream circulation. In addition,[...]

02 May

Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé

During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Nanoligent, whoes founders are leaders of NANBIOSIS units, raises €1M in Series Seed financing

Barcelona, Spain – Milan, Italy, February 3rd, 2022 – Nanoligent SL, a biotech company specialized in the development of nanotechnology-based cancer treatments, today announces the completion of the first closing of a Seed financing round of €1M. The round has been led by members of Italian Angels for Growth, the largest network of business angels in Italy, through the investment vehicle Nanolinvest, and AVANTECA Partners, a Swiss privately held asset management firm, both specialized in supporting innovative early-stage life-science companies primarily in Europe. An equity campaign, is still ongoing on Doorway, an online investment platform, thus promising to provide additional funding[...]

11 Jan

The activity of Peptide T22 as antimicrobial drug opens new possibilities for the local control of bacterial infections related to tumors

Researchers of NANBIOSIS Units 1 and 18, from CIBER-BBN at the Institut de Biotecnologia i de Biomedicina (IBB-UAB) and the Institut de Recerca Sant Pau (IIB-Sant Pau) presents the finding of a significant antimicrobial activity in the targeting peptide T22, which is used for antitumor therapy directed against CXCR4 + stem cells, with clinical interest in more than 20 types of human cancer, including colorectal cancer. The study describes how said activity has a significant effect on several bacterial species of clinical importance: “we have detected antimicrobial activity associated with T22 and inhibition of biofilm formation on Escherichia coli, Staphylococcus[...]

18 Apr

Collaboration of two NANBIOSIS units in the Valorisation Project “ADVERT”

The Project ADVERT (Advanced Extracellular Vesicles for Enzyme Replacement Therapy) is a research valorisation project recently granted by CIBER. The project pursues to advance the development of extracellular vesicles as treatments for lysosomal diseases, specially to bring new therapies to treat FABRY disease. The ADVERT Project will count on the active particpation of two NANBIOSIS units of CIBER-BBN: Unit 20 of the ICTS NANBIOSIS at Vall d’Ebrón Hospital, led by Ibane Abasolo, who coordinates the project. Unit 1 Protein Production Platform (PPP), at the IBB-UAB, led by Neus Ferrer, throught the coordination in the project of José Luis Corchero. T[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

25 Feb

An Auristatin-based nanoconjugate reduces leukemia burden in a disseminated AML model

Researchers of the Nanotoxicology Unit of the the CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), leaded by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and of the NANBIOSIS (nanbiosis.es) Protein Platform (u1-protein-production-platform-ppp) leaded by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have developed a novel protein-Auristatin nanoconjugate that specifically targets CXCR4-overexpressing acute myeloid leukemia (AML) cells. It selectively accumulates in target cancer cells expressing this receptor and deliver the toxin Auristatin within their cytosol. There, Auristatin potently blocks microtubule polymerization, provoking mitotic catastrophe,[...]